Project Summary/Abstract The purpose of the Biomarkers Core is to provide an organizational model to accelerate the development and approval of biomarker tests that link biology to clinical outcomes within SPORE projects and across other Cores. This Core is focused on credentialing both imaging-based and liquid non-invasive assays to assess and monitor disease status by characterizing the molecular and cellular features of a cancer as it changes over time. Through the Biomarkers Core, the collection of human biospecimens is scheduled, collected, and tracked under an IRB-approved clinical protocol. The process of consent, patient registration, and specimen collection is undertaken in clinic, under the leadership of the Biomarkers Core. Applied to the clinic, the Biomarkers Core efforts cover patients across the prostate cancer disease continuum. The Biomarkers Core will also conduct under its leadership the three imaging protocols, for FDHT, PSMA, and DLL3 PET. This core complements the other SPORE cores and MSK resources that include the Center for Molecular Oncology (CMO), Sloan Kettering Institute (SKI), the Human Oncology and Pathogenesis Program (HOPP), Clinical Laboratories, the Early Drug Development (EDD) Service, and other clinical services. Priorities for the Core are determined by unmet needs in basic research, drug development, and clinical practice, with the objective of enabling more informed diagnostic and therapeutic decisions so that patient outcomes are improved.

Project Narrative Designed to complement both research projects and other Cores within the MSK SPORE in Prostate Cancer, the goal of the Biomarkers Core is to accelerate the development and approval of biomarker tests that link biology to clinical outcomes. This will enable more informed diagnostic and therapeutic decisions, so that patient outcomes are improved.